[This is the PR BMY issued in conjunction with the half-day investor presentation last week. Non-GAAP EPS in 2013, the first year in which mega-blockbuster Plavix will be off-patent in the US and other major jurisdictions, is expected to be at least $1.95. (BMY’s 2010 non-GAAP EPS guidance is $2.15-2.25; no guidance has been given for 2011-2012.)
The 2013 EPS forecast is based on probability-weighted contributions from five consequential drugs BMY hopes to launch between now and 2013: apixaban for thrombosis (#msg-47461590); belatacept for organ-transplant rejection (#msg-47249910); brivanib for HCC (a major disease in Asia); ipilimumab for melanoma and other solid cancers; and dapagliflozin for type-2 diabetes. BMY also expects continued growth of its antiviral franchise consisting of Reyataz, Sustiva (Atripla), and Baraclude.
BMY pays an annual dividend of $1.28/sh and has a rock-solid balance sheet to ensure that the dividend will not be cut. Thus, an investor might view BMY’s stock as a pseudo convertible bond that pays a 5.2% yield and contains a call option on the drug pipeline. Alternatively, an investor might consider BMY a buyout candidate for one of the *big* Big Pharma during the next couple of years, which is the way I prefer to look at it (#msg-47469186).]
›Bristol-Myers Squibb to Highlight Strong Pipeline and Execution of BioPharma Strategy in Meeting with Investment Community
Thursday March 4, 2010, 7:30 am EST
NEW YORK--(BUSINESS WIRE)--During a meeting with the investment community today, Bristol-Myers Squibb Company (NYSE: BMY ) will provide a comprehensive business overview, highlight positive pipeline developments and provide 2013 minimum non-GAAP earnings per share guidance.
“In December 2007, we outlined a strategy and a set of deliverables. Since then we have delivered consistently by executing relentlessly on our BioPharma strategy, meeting our commitments and sustaining excellent operational and financial performance,” said James M. Cornelius, chairman and chief executive officer. “We have fundamentally differentiated ourselves from our peers as a focused biopharmaceutical company that is well-positioned to deliver on the promise of our pipeline.”
The company expects 2013 non-GAAP earnings per share to be, at minimum, $1.95, setting a base for sustained growth expected to begin in 2014. The company also expects 2013 to be the first full year of impact from the loss of Plavix patent exclusivity in the U.S.
During today’s meeting, the company also plans to provide an update on its successful transformation into a next-generation BioPharma leader, outline key strategic imperatives and the company’s overall outlook.
“I am fully confident in our ability to deliver on our three major strategic imperatives -- driving our performance in the next few years, improving our earnings base in 2013 and sustaining growth in 2014 and beyond,” said Lamberto Andreotti, president and chief operating officer. “We have important strategic, operational and financial levers which will allow us to fully realize our potential as a BioPharma leader, and to deliver on our near-term and long-term growth opportunities.”
INVESTMENT COMMUNITY MEETING HIGHLIGHTS
Bristol-Myers Squibb management will review key accomplishments as part of its BioPharma transformation, highlight strategic imperatives that will drive near-term growth and provide an in-depth overview of the company’s late-stage and early development pipeline, in particular the company’s progress in Alzheimer’s disease and hepatitis C.
Management will also provide an overview of its plans to execute its key imperatives by driving top-line revenue growth from current and potentially new products, delivering on the pipeline, building on progress made in productivity initiatives and the use of cash, working capital and other financial tools to invest in the future.
In addition, management will discuss key revenue drivers such as PLAVIX®, ABILIFY® and the HIV portfolio, which continue to demonstrate solid global growth. More recent launches such as ORENCIA®, SPRYCEL™ and BARACLUDE® have also continued to grow rapidly and are becoming established leaders in their respective therapeutic areas.
The company also will highlight ONGLYZA™ and promising trends which have been realized since its launch in 2009. Five other compounds -- apixaban, belatacept, brivanib, dapagliflozin and ipilimumab -- are expected to be launched by 2012, subject to regulatory approval. In combination, these compounds represent a significant transformation of company’s BioPharma portfolio and are expected to drive growth in 2013 and beyond.
2013 GUIDANCE
The 2013 minimum non-GAAP EPS guidance of $1.95 excludes any potential impact of U.S. healthcare reform and the impact of business development (String of Pearls) activities in addition to specified items described under “Use of Non-GAAP Financial Information” below. The guidance further assumes strong underlying revenue trends for certain key products, continued and additional productivity savings, significant contributions from pipeline products that are expected to receive regulatory approval, and regulatory approval of new indications for several currently marketed products, and exclusivity for ABILIFY through the term of the current agreement with Otsuka Pharmaceutical Co., Ltd.‹
Market Data 
Markets 
AI
